

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**REGENERON PHARMACEUTICALS, INC.,**  
Petitioner

v.

**NOVARTIS PHARMA AG,**  
**NOVARTIS TECHNOLOGY LLC,**  
**NOVARTIS PHARMACEUTICALS CORPORATION,**  
Patent Owners

---

**IPR2021-00816**  
U.S. Patent 9,220,631

---

**NOTICE OF CERTIFICATION OF WORD COUNTS FOR  
PATENT OWNERS' SURREPLY TO PETITIONER'S REPLY**

Patent Owner Novartis hereby supplements the Certificate of Word Count for the Patent Owner's Surreply to Petitioner's Reply, filed on May 26, 2022. The Certificate of Word Count was inadvertently not included in Patent Owner's Surreply to Petitioner's Reply, filed on May 26, 2022.

**CERTIFICATE OF WORD COUNT**

Under 37 C.F.R. § 42.24(b)(1), the undersigned certifies that the foregoing Patent Owner's Surreply to Petitioner's Reply contains 5,565 words, excluding table of contents, and a certificate of service or word count, as measured by the word-processing system used to prepare this paper. 37 CFR. § 42.24(a)(1).

Dated: May 27, 2022

By: *Elizabeth J. Holland*  
Elizabeth J. Holland (Reg. No. 47,657)  
Lead Counsel for Patent Owners  
ALLEN & OVERY LLP  
1221 Avenue of the Americas  
New York, NY 10020  
Phone: (212) 610-6300  
[elizabeth.holland@allenovery.com](mailto:elizabeth.holland@allenovery.com)

**CERTIFICATE OF SERVICE**

A copy of this **Notice of Certificate of Word Count for Patent**

**Owners' Surreply to Petitioner's Reply** has been served on Petitioner's attorneys of record as follows via electronic mail:

Elizabeth Stotland Weiswasser  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8022  
F: 212-310-8007  
elizabeth.weiswasser@weil.com  
USPTO Reg. No. 55,721

Anish R. Desai  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8730  
F: 212-310-8007  
anish.desai@weil.com  
USPTO Reg. No. 73,760

Natalie Kennedy  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153  
T: 212-310-8730  
F: 212-310-8007  
natalie.kennedy@weil.com  
USPTO Reg. No. 68,511

Andrew Gesior  
Weil, Gotshal & Manges LLP  
767 Fifth Avenue  
New York, NY 10153

T: 212-310-8730  
F: 212-310-8007  
andrew.gesior@weil.com  
USPTO Reg. No. 76,588

Brian E. Ferguson  
Weil, Gotshal & Manges LLP  
2001 M Street, N.W., Suite  
600  
Washington, D.C. 20036  
T: 202-682-7000  
F: 202-857-0940  
brian.ferguson@weil.com  
USPTO Reg. No. 36,801

Christopher M. Pepe  
Weil, Gotshal & Manges LLP  
2001 M Street, N.W., Suite  
600  
Washington, D.C. 20036  
T: 202-682-7000  
F: 202-857-0940  
christopher.pepe@weil.com  
USPTO Reg. No. 73,851

Regeneron.IPR.Service@weil.com

***Attorneys for Regeneron Pharmaceuticals, Inc.***

Dated: May 27, 2022

By: /Frank ReDavid/  
Frank ReDavid  
Litigation Specialist  
Allen & Overy LLP